Anne-Laure Chabanon
Sanofi Pasteur
8 Papers
20 Citations
Anne-Laure Chabanon is an academic researcher from Sanofi Pasteur. The author has contributed to research in topics: Reactogenicity & Vaccination. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season
Sonja Gandhi-Banga,Anne-Laure Chabanon,Cécile Eymin,Timothy David Caroe,Karina Butler,Annick Moureau +5 more
TL;DR: An enhanced passive safety surveillance for a trivalent split-virion inactivated influenza vaccine, an intradermal version of this vaccine, and a recently licensed quadrivalent version (IIV4; VaxigripTetraTM) during the 2017/18 influenza season in the UK and Republic of Ireland found no change was found compared to the known or expected AR rates.
12
Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season
TL;DR: The 2018/19 EPSS showed no clinically significant change from the expected safety profiles of IIV3 and IIV4 vaccines, and the most frequent ARs were vaccination site pain and fever for IIV 3, and vaccination sitePain, vaccination site inflammation, myalgia, and headache for IIv4.
12
Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season.
TL;DR: In this paper, a passive safety surveillance of individuals vaccinated with the quadrivalent inactivated split-virion influenza vaccine (IIV4) during routine immunization in Finland during the 2019/20 season was carried out.
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study
Paul A. Goepfert,Bo Fu,Anne-Laure Chabanon,Matthew Bonaparte,Matthew Davis,Brandon Essink,Ian Frank,Owen Haney,Helene Janosczyk,Michael C. Keefer,Marguerite Koutsoukos,Murray A Kimmel,Roger Masotti,Stephen Savarino,Lode Schuerman,Howard J. Schwartz,Lawrence D Sher,Jon Smith,Fernanda Tavares-Da-Silva,Sanjay Gurunathan,Carlos A. DiazGranados,Guy deBruyn +21 more
TL;DR: In this article, the interim safety and immunogenicity results of the first-in-human study of the CoV2 preS dTM vaccine with two different adjuvant formulations were presented.
Safety of a quadrivalent influenza vaccine in Vietnamese healthy subjects aged 6 months and older.
Vu Dinh Thiem,Anne-Laure Chabanon,Marion Fournier,Nathalie Lavis,Nguyen Dang Quang,Vu Hai Ha,Melvin Sanicas +6 more
TL;DR: The results suggest that QIV is well tolerated across age groups in Vietnam, and can be safely used to protect the Vietnamese population against influenza and its potentially serious complications.
6